ALNYAlnylam PharmaceuticalsNeutralAlnylam Pharmaceuticals
2d ago on
After $ALNY we'll see the CCO of the next oligoRx stalwart to lose his job.
View original →
Opportunistic biotech trading bitch with a focus on nucleic acid-based and -targeted biotech. Fiercely independent. https://t.co/dfLqOuH7Uh
Cite asCryptoQuant has tracked the directional calls on ALNY by @RNAiAnalyst on X since Aug 2025: not yet scored on ALNY (as of Nov 11, 2026).
Other assets covered (14)
3 ALNY calls on record, a thin history.
Relative view by default: fewer than 30 ALNY calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @RNAiAnalyst to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
After $ALNY we'll see the CCO of the next oligoRx stalwart to lose his job.
View original →$ARGX looked at $ALNY and decided to do M&A in the hot macrocyclic peptide space. $PTGX https://t.co/Ca9zPvBB2l
View original →$ALNY, also following the ouster of CCO, needs to ask itself why $BBIO is able to position itself as first-in-line, but Alnylam just tries to be 2nd line post-tafamidis...or at best combo treatment. Short of a direct head-to-head, there should be real world data show-down between vutri and acoramidis.
View original →I expect $aapl to soon suffer the same fate as $ALNY: did not pay to play (in AI, extrahepatic) when they could have easily afforded it; will have to play catch-up from position of technological weakness.
View original →A changing of the guards in #RNAi in 2027? Stale chip vendor $ARWR to surpass $ALNY in market cap?
View original →
